TY - JOUR
T1 - Effect of parenteral lipid emulsion on preterm infant PUFAs and their downstream metabolites
AU - Suganuma, Hiroki
AU - Collins, Carmel T.
AU - McPhee, Andrew J.
AU - Leemaqz, Shalem
AU - Liu, Ge
AU - Andersen, Chad C.
AU - Bonney, Dennis
AU - Gibson, Robert A.
N1 - Funding Information:
This work was supported by a grant from the Women's and Children's Hospital Foundation and the National Health and Medical Research Council (NHMRC) Centre for Research Excellence (APP1135155). The funders were not involved in the study design nor in the collection, analysis, and interpretation of data or the decision to submit for publication. Dr Suganuma was supported by an overseas study scholarship from Kamisu Saiseikai Hospital, Ibaraki Prefecture, Japan. A/Professor Collins and Professor Gibson are in receipt of NHMRC Fellowships (APP1132596 and APP1046207 respectively). The views expressed in this article are solely the responsibility of the authors and do not reflect the views of the NHMRC.
Funding Information:
We gratefully thank the infants and their families who participated in this study, as well as all our medical, nursing and midwifery colleagues in the Neonatal Intensive Care Unit and Special Care Baby Unit of the Women's and Children's Hospital without whom this research would not have been possible.’
Publisher Copyright:
© 2020
PY - 2021/1
Y1 - 2021/1
N2 - Objective: Oxylipins synthesized by oxidation of long-chain polyunsaturated fatty acids (LCPUFAs) are bioactive downstream lipid mediators. The aim of this study was to describe oxylipin levels in preterm infants born 30 to 33 weeks’ gestation who were enrolled in a randomized controlled trial in which peripheral parenteral nutrition (P-PN), including lipid emulsion (containing soy, medium chain triglyceride, olive and fish oil), was compared with 10% glucose on growth during the transition to enteral feeds. Methods: Of the 92 infants randomized to the P-PN study, the first 72 (P-PN n = 34, control n = 38) had blood taken for fatty acid analyses. P-PN infants received parenteral nutrition including 3% protein, 8% glucose and 17% SMOFlipid® lipid (containing soy, medium chain triglyceride, olive and fish oil), and control infants 10% glucose. Both groups commenced enteral feeds when clinically stable. 32 oxylipins and 5 free fatty acids were screened (using ultra-high-performance liquid chromatography–tandem mass spectrometry), and 5 total LCPUFA were measured (using gas chromatography), on study days 1 (baseline), 2, 4, 7, 14 and 21. Results: Both total and free LA, ALA and EPA were significantly higher in the P-PN group compared with control over the first week of life. Whereas total AA was significantly lower and free DHA significantly higher over the same time period. All LA, ALA, EPA and four DHA derived oxylipins detected were significantly higher in the P-PN group compared with the control group during the first week of life, with three AA derived oxylipins significantly lower and one significantly higher. Conclusions: Parenteral lipid emulsion resulted in a change in total and free fatty acids and related oxylipins with the profiles suggesting increased omega-6 driven inflammation. Further studies to investigate the association between the oxylipin levels and nutrition and to determine whether the oxylipin profiles influence the clinical outcome in preterm infants are warranted.
AB - Objective: Oxylipins synthesized by oxidation of long-chain polyunsaturated fatty acids (LCPUFAs) are bioactive downstream lipid mediators. The aim of this study was to describe oxylipin levels in preterm infants born 30 to 33 weeks’ gestation who were enrolled in a randomized controlled trial in which peripheral parenteral nutrition (P-PN), including lipid emulsion (containing soy, medium chain triglyceride, olive and fish oil), was compared with 10% glucose on growth during the transition to enteral feeds. Methods: Of the 92 infants randomized to the P-PN study, the first 72 (P-PN n = 34, control n = 38) had blood taken for fatty acid analyses. P-PN infants received parenteral nutrition including 3% protein, 8% glucose and 17% SMOFlipid® lipid (containing soy, medium chain triglyceride, olive and fish oil), and control infants 10% glucose. Both groups commenced enteral feeds when clinically stable. 32 oxylipins and 5 free fatty acids were screened (using ultra-high-performance liquid chromatography–tandem mass spectrometry), and 5 total LCPUFA were measured (using gas chromatography), on study days 1 (baseline), 2, 4, 7, 14 and 21. Results: Both total and free LA, ALA and EPA were significantly higher in the P-PN group compared with control over the first week of life. Whereas total AA was significantly lower and free DHA significantly higher over the same time period. All LA, ALA, EPA and four DHA derived oxylipins detected were significantly higher in the P-PN group compared with the control group during the first week of life, with three AA derived oxylipins significantly lower and one significantly higher. Conclusions: Parenteral lipid emulsion resulted in a change in total and free fatty acids and related oxylipins with the profiles suggesting increased omega-6 driven inflammation. Further studies to investigate the association between the oxylipin levels and nutrition and to determine whether the oxylipin profiles influence the clinical outcome in preterm infants are warranted.
KW - Free fatty acids
KW - Lipid emulsion
KW - Oxylipin
KW - Polyunsaturated fatty acids
KW - Preterm infant
UR - http://www.scopus.com/inward/record.url?scp=85097377668&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2020.102217
DO - 10.1016/j.plefa.2020.102217
M3 - Article
C2 - 33291053
AN - SCOPUS:85097377668
SN - 0952-3278
VL - 164
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
M1 - 102217
ER -